Ken Miyaguchi, PhD, received his doctorate in medical science from the Tokyo Medical and Dental University, Japan, in 2012. He worked as a specially appointed assistant professor, investigating breast cancer until 2015. As a postdoctoral associate at Weill Medical College of Cornell University, New York, Miyaguchi studied a novel brain tumor model generated from hESC-derived cerebral organoid with patient-derived glioma stem cells. He joined the Yu Laboratory as a project scientist in 2018. Miyaguchi’s current focus is on translating basic cancer research and immunotherapy targeting glioma stem cells into effective therapies for patients with brain tumors.